# Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer

> **NCT01003808** · PHASE1 · COMPLETED · sponsor: **ImmunoFrontier, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **BIOLOGICAL:** IMF-001

## Key facts

- **NCT ID:** NCT01003808
- **Lead sponsor:** ImmunoFrontier, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-03
- **Final completion:** 2012-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01003808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01003808, "Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01003808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*